Which antiplatelet medication is best after a coronary stent? The costly and potential life-or-death question lingers after most of the 600,000 angioplasties performed every year in the United States. ...

Mayo Clinic researchers have shown that a molecule called Cul4 helps to deposit DNA-packaging histone proteins onto DNA, an integral step in cramming yards of genetic code into compact coils that can fit into each cell. When DNA isn’t packaged correctly, it can lead to the genomic instability characteristic of many forms of cancer. The research is published in the Nov. 7 issue of the journal Cell. The results explain on a molecular level how Cul4 enables the handoff of histones from the proteins escorting them from their birthplace in the cell to their workplace on the DNA, where they can begin wrapping DNA up into tidy units called nucleosomes.  “We suggest that cancer cells may have evolved a mechanism to disrupt proper nucleosome assembly by altering Cul4 and other factors, which in turn could affect the stability of the genome and promote the formation of tumors,” says senior study author Zhiguo Zhang, Ph.D., a molecular biologist at Mayo Clinic.

Researchers at Mayo Clinic, and the Center for Individualized Medicine, have recently been utilizing genomic sequencing to help develop personalized care treatments for men with castration-resistant prostate cancer, a progressive and incurable stage of prostate cancer that no longer responds to hormone therapies that stop or slow testosterone production. “Men with castration-resistant prostate cancer have abysmal survival rates, typically living an average of two years once hormone therapies fail,” says Manish Kohli, M.D., a Mayo Clinic oncologist and principal investigator of the Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study. The FDA has recently approved several new therapies for use in treating castration-resistant prostate cancer. Many questions remain, however, over which medications to use in individual cases. Researchers and doctors utilize exome sequencing and RNA profiling in the PROMOTE study, to identify biomarkers within prostate cancers that can help identify the optimal drug for each individual patient.

  35,000 and Growing This week, the Biobank recruited its thirty-fifth-thousandth participant, and we're still growing. With every patient who graciously agrees to have ...

At Mayo Clinic, the Center for Individualized Medicine oversees the Biorepositories Program, which is a collection of biospecimens, such as tissue, blood, plasma, serum, urine, DNA, RNA and live cells, from patients and research volunteers. These biospecimens are used throughout the clinic for researches to utilize for a broad range of tests and research.

    I've been a paraplegic and a Mayo Clinic patient for over 10 years. My legs decided to stop working in ...

...

http://www.youtube.com/watch?v=LFaI2xAaj7g&feature=share&list=PLE4A384A799EFD6C4 The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer (CPRC) that may identify an individualized treatment ...

Researchers at Mayo Clinic recently found that a specific pair of proteins may be a successful prognostic biomarker for identifying smoking-related lung cancers. The clinical significance of neuroendocrine (NE) differentiation in lung adenocarcinoma (AD), and the most appropriate biomarkers for this assessment, has long been debated. In the absence of a gold standard, investigators have most commonly used immunohistochemical (IHC) staining of one or a combination of NE markers, such as chromogranin (CHGA), synaptophysin (SYP), neuron-specific enolase or neural cell adhesion molecule (CD56/NCAM) to assess the role of NE differentiation in lung cancer survival. Notably, previous reports have not included ASCL1, despite the pivotal role this gene has in the development of NE cells in the lung.

http://www.youtube.com/watch?v=n-Y-MUIuPE8&list=PLE4A384A799EFD6C4&index=20   Today's Twitter Chat with Dr. Richard Besser from ABC on the topic of Breast Cancer touched on the need for mammogram ...

  A Mayo Clinic researcher, and collaborators, have shown that an individual's diet and genomic makeup interact to determine which microbes exist and how they ...

    The Individualized Medicine Conference, hosted by Mayo Clinic Center for Individualized Medicine made a big wave in the world of genomics, ...